A single enzyme that can generate all four nucleoside triphosphates, the building blocks of ribonucleic acid (RNA), has been ...
A U.S.-based clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The company conducts ...
Ianalumab targets the BAFF receptor, depleting malignant B cells and enhancing ibrutinib's efficacy, offering a potential ...
Precise methods for shredding or repairing and replacing specific cancer-causing proteins in a malignant cell, developed at ...
A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
The Daily Galaxy on MSN
Main cause of sunburn finally revealed, and it’s not the reason we’ve always believed
Scientific consensus on the biological mechanisms underpinning sunburn has remained largely unchanged for decades. The ...
FDA grants Priority Review and assigns a PDUFA goal date of July 17, 2026MINNEAPOLIS, (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: ...
New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...
Hyderabad: Scientists from IIT Hyderabad and CSIR–Indian Institute of Chemical Technology (CSIR-IICT) have developed a novel ...
Detailed price information for Ascentage Pharma Group Intl ADR (AAPG-Q) from The Globe and Mail including charting and trades.
Despite a significant 48.8% objective response rate and breakthrough therapy status, this regulatory shift reverses years of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback